Should I take senolytics (D+Q, fisetin)?

Senolytic compounds clear senescent cells in mice. Human RCT data is preliminary.

Our read is Limited Research. The mechanistic story is plausible and the early signals are interesting, but the human outcome data is thin: a limited evidence base (42/100) and only thin support (38% consensus). At $200/month, taking senolytics (D+Q, fisetin) is a bet on preliminary science rather than a settled recommendation.

Pulled the public claims about taking senolytics (D+Q, fisetin) from proponents on file (a tracked voice) and weighed them against the more cautious voices (a tracked voice), then cross-checked each against the primary trial and cohort literature and the prevailing clinical guidance. We grade the claim against what the human evidence actually supports, not against how confidently it is stated.

• 01Expert consensus: 38% — thin support among the voices we track.
• 02Evidence strength: 42/100, which we read as a limited evidence base.
• 03Human outcome data on taking senolytics (D+Q, fisetin): sparse, short, and underpowered. Most of the case rests on mechanism or animal models.
• 04Replication: the headline findings have not been independently confirmed at scale.
• 05Commercial gap: the protocols sold to the public are ahead of the trials that would justify them.